Get 50% OFF This Monsoon!
Emmessar Biotech & Nutrition
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Emmessar Biotech & Nutrition Ltd, originally started on 17th March 1992 as Emmessar Chemical Industries Ltd (ECIL) started with its operations manufacturing Super Specialty Fine Chemicals. In its in-house R&D, the Company succeeded in developing many Specialty Fine Chemicals. ECIL gained official recognition for its R&D from DSIR, Ministry of Science & Technology, Government of India, New-Delhi in early 1996.
On realizing that some of the specialty chemicals developed & exported to USA & Europe was being used in producing healthcare formulations, the Company plunged into a new venture in the Healthcare business, where phenomenal growth in the coming decades was anticipated.
ECIL's research team established that the specialty chemicals made by them had potential as 'Vital Micro Nutrients', used worldwide in research as 'tools' of Biotechnology. The Company's management took opportunity to also enter the field of Biotechnology & Healthcare, at a time when across the world, healthcare ranked high in priority in both manufacturer's and consumer's minds.
To better represent its new core activity, a change in the company's name from Emmessar Chemical Industries Ltd (ECIL) to Emmessar Biotech & Nutrition Ltd (EBNL) on April 7, 2000, became essential.
EBNL's R&D pursued its research and while identifying potential markets for their products in Healthcare, the Company in 1998, entered into collaborative partnership with California based, Vibrant Life, a company well established and reputed in the USA.
The intellectual exchange of concepts and technology between Emmessar Biotech & Nutrition Ltd., and Vibrant Life, led to path-breaking discoveries (VedaCeuticals) through a combination of core fundamentals of Nutraceuticals, Cosmeceuticals, Ayurveda, Biotechnology and Nanotechnology - giving a new dimension to future products emerging from the stable.
EBNL's range of products covers different aspects and unmet needs of Healthcare. They cater to and address obstinate skin problems, muscle problems, bone problems and other debilitating chronic physical ailments.
EBNL is a Public Limited Company, with a paid-up Share Capital of about Rs. 50.00 million (over US$ 1.00 million). The Company's stocks are traded on The Bombay Stock Exchange Ltd.
Emmessar Biotech & Nutrition share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Emmessar Biotech & Nutrition indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Emmessar Biotech & Nutrition is valued compared to its competitors.
Emmessar Biotech & Nutrition PE ratio helps investors understand what is the market value of each stock compared to Emmessar Biotech & Nutrition 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Emmessar Biotech & Nutrition evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Emmessar Biotech & Nutrition generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Emmessar Biotech & Nutrition in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Emmessar Biotech & Nutrition shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Emmessar Biotech & Nutrition compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Emmessar Biotech & Nutrition over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Emmessar Biotech & Nutrition helps investors get an insight into when they can enter or exit the stock. Key components of Emmessar Biotech & Nutrition Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Emmessar Biotech & Nutrition shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Emmessar Biotech & Nutrition ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Emmessar Biotech & Nutrition provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Emmessar Biotech & Nutrition highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Emmessar Biotech & Nutrition .
The balance sheet presents a snapshot of Emmessar Biotech & Nutrition ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.